Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience

• Published in: Clinical and experimental medicine 2023-08, Vol.23 (4), p.1197-1203
• Main Authors: Baratè, Claudia, Caruso, Teresita, Mavilia, Fabrizio, Sammuri, Paola, Pratesi, Federico, Motta, Giuseppe, Guerri, Valentina, Galimberti, Sara, Migliorini, Paola
• Format: Article
• Language: English
• Subjects: Antibodies; Antibodies, Neutralizing; Antibody response; Avidity; Chronic lymphocytic leukemia; Clonal selection; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Flow cytometry; Hematology; Humans; Immune response; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Internal Medicine; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes; Medicine; Medicine & Public Health; mRNA; Oncology; Original; Original Article; Peripheral blood; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccines
• ISSN: 1591-9528; 1591-8890; 1591-9528
• DOI: 10.1007/s10238-022-00877-2

Vaccination represents the best strategy to fight COVID-19 pandemics, especially in immune compromised subjects. In chronic lymphatic leukemia patients, a marked impairment of the immune response to mRNA SARS-CoV-2 vaccine was observed. In this report, we analyzed anti-RBD and neutralizing antibodies in CLL patients after two doses of mRNA SARS CoV 2 vaccine and evaluated the impact of Bruton kinase inhibitory agents. Twenty-seven CLL patients vaccinated with mRNA vaccines against SARS CoV-2 were recruited. Serum IgG, IgM and IgA anti-RBD antibodies and neutralizing antibodies were detected, and antibody avidity was measured. Peripheral blood leukocytes subsets were evaluated by flow cytometry. After two vaccine doses anti-RBD IgG were produced in 11/27 (40.5%) of patients and levels of IgG and IgA anti RBD in CLL patients were sensibly lower than in controls. Neutralizing antibodies were detectable in 12/27 (44.5%) of the patients and their level was lower than that observed in controls. Disease burden and treatment with Bruton kinases inhibitors markedly impaired vaccine induced antibody response. However, in responder patients, antibody avidity was comparable to normal subjects, indicating that the process of clonal selection and affinity maturation takes place as expected. Taken together, these data confirm the impact of disease burden and therapy on production of anti-RBD and neutralizing antibodies and support the current policy of vaccinating CLL patients.